Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Celldex Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Celldex Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Celldex Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Celldex Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Celldex Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Celldex Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Celldex Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Celldex Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Celldex Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Celldex Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Celldex Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celldex Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Celldex Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Celldex Therapeutics, Inc. Snapshot 5 Celldex Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Celldex Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Celldex Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Celldex Therapeutics, Inc. - Pipeline Products Glance 13 Celldex Therapeutics, Inc. - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Celldex Therapeutics, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Celldex Therapeutics, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Celldex Therapeutics, Inc. - Drug Profiles 17 glembatumumab vedotin 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 rindopepimut 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CDX-1401 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CDX-301 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CDX-2401 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 varlilumab 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CDX-014 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CDX-1189 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Celldex Therapeutics, Inc. - Pipeline Analysis 28 Celldex Therapeutics, Inc. - Pipeline Products by Target 28 Celldex Therapeutics, Inc. - Pipeline Products by Route of Administration 30 Celldex Therapeutics, Inc. - Pipeline Products by Molecule Type 31 Celldex Therapeutics, Inc. - Pipeline Products by Mechanism of Action 32 Celldex Therapeutics, Inc. - Recent Pipeline Updates 34 Celldex Therapeutics, Inc. - Dormant Projects 42 Celldex Therapeutics, Inc. - Discontinued Pipeline Products 43 Discontinued Pipeline Product Profiles 43 CDX-1135 43 Celldex Therapeutics, Inc. - Company Statement 44 Celldex Therapeutics, Inc. - Locations And Subsidiaries 50 Head Office 50 Other Locations & Subsidiaries 50 Celldex Therapeutics, Inc. - Key Manufacturing Facilities 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 53 Disclaimer 53
List of Tables Celldex Therapeutics, Inc., Key Information 5 Celldex Therapeutics, Inc., Key Facts 5 Celldex Therapeutics, Inc. - Pipeline by Indication, 2014 7 Celldex Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Celldex Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Celldex Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2014 11 Celldex Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Celldex Therapeutics, Inc. - Phase III, 2014 13 Celldex Therapeutics, Inc. - Phase II, 2014 14 Celldex Therapeutics, Inc. - Phase I, 2014 15 Celldex Therapeutics, Inc. - Preclinical, 2014 16 Celldex Therapeutics, Inc. - Pipeline by Target, 2014 28 Celldex Therapeutics, Inc. - Pipeline by Route of Administration, 2014 30 Celldex Therapeutics, Inc. - Pipeline by Molecule Type, 2014 31 Celldex Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 33 Celldex Therapeutics, Inc. - Recent Pipeline Updates, 2014 34 Celldex Therapeutics, Inc. - Dormant Developmental Projects,2014 42 Celldex Therapeutics, Inc. - Discontinued Pipeline Products, 2014 43 Celldex Therapeutics, Inc., Other Locations 50 Celldex Therapeutics, Inc., Subsidiaries 50 Celldex Therapeutics, Inc., Key Manufacturing Facilities 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.